cailynnjohnson

Neutralizing Antibodies in Research: Expanding Tools for Functional Studies and Ion Channel Biology

Neutralizing antibodies have become essential tools across biomedical research, enabling scientists to block receptor–ligand interactions, dissect signaling pathways, and study pathogen entry mechanisms with increasing precision. As research questions grow more specialized, the need for rigorously validated antibody reagents—both broad‑spectrum and highly targeted—continues to rise.   The Expanding Utility of Neutralizing Antibodies In many experimental…

Read More

Phage Display Vaccines: New Possibilities for Antigen Presentation and Vaccine Research

A 2026 study of a lambda phage platform targeting EGFRvIII highlights the potential of multivalent antigen display, while underscoring the challenges of translating experimental vaccine designs into effective immunization strategies. What the 2026 EGFRvIII Study Demonstrated In March 2026, NIH-affiliated scientists reported a lambda (λ) bacteriophage engineered to display an EGFRvIII-derived 13-amino-acid peptide. EGFRvIII is…

Read More

Anti-GM3 Antibodies: Overcoming Specificity Challenges in Cancer Glycan Research

A 2026 preclinical study of a GM3-based vaccine incorporating a lipid A mimetic highlights progress in carbohydrate antigen presentation, while underscoring persistent challenges in anti-glycan antibody development. A 2026 GM3 Vaccine Study and the Antibody Development Question GM3 is a ganglioside studied as a tumor-associated carbohydrate antigen in melanoma. In a 2026 Journal of Medicinal…

Read More

Why Parkinson’s Drug Discovery Needs Better Human Models

Parkinson‘s drug discovery is constrained by species differences, patient variability, and imperfect laboratory models. Learn how human iPSC-derived neurons and brain organoids can improve disease modeling and preclinical decisions.   Parkinson’s disease research faces a familiar but costly problem: a compound can show promise in a laboratory model yet fail to produce meaningful benefits in…

Read More

Why Parkinson’s Drug Discovery Needs Better Human Models

Parkinson‘s drug discovery is constrained by species differences, patient variability, and imperfect laboratory models. Learn how human iPSC-derived neurons and brain organoids can improve disease modeling and preclinical decisions.   Parkinson’s disease research faces a familiar but costly problem: a compound can show promise in a laboratory model yet fail to produce meaningful benefits in…

Read More

Why Droplet Microfluidic Chips Can Struggle With Reproducibility

Microfluidic chips can streamline research, but inconsistent droplets, material incompatibility, and disconnected workflows can waste samples and time. Learn how informed chip selection and system-level validation can improve reliability.   Microfluidic chips can conserve samples and provide precise control over tiny fluid volumes. Yet a device that works during a demonstration may require reoptimization when…

Read More

Liposome-Based Adjuvants: Beyond Higher Antibody Titers

High antibody titers do not always reveal the full quality of vaccine-induced immunity. Explore how liposome-based adjuvants can shape functional responses—and why stability, characterization, and scale-up remain critical hurdles.   For developers of protein subunit and peptide vaccines, selecting a promising antigen is only the beginning. Purified antigens can produce limited immune stimulation, while conventional…

Read More

CAR-T’s Next Frontier: Cell-Free Exosomes vs. Solid Tumor Barriers

CAR-T stalls in solid tumors due to CRS, poor stromal penetration, and costly manufacturing. Cell-free CAR-exosomes offer a cell-free approach with a distinct preclinical safety profile — but donor selection and potency validation remain key pain points. Integrated engineering bridges the gap. CAR-T cell therapy has transformed hematologic cancer treatment — yet clinical activity in…

Read More